The possible role of heme oxygenase and its byproduct carbon monoxide (CO) in the regulation of blood pressure is under investigation. The aim of this study was to compare end tidal breath CO (ETCO) levels in women with gestational hypertension (GH) or pre-eclampsia to the levels in healthy pregnant and nonpregnant women.
INTRODUCTION
Hypertensive disorders during pregnancy are the second leading cause of maternal death in the United States and contribute significantly to neonatal morbidity and mortality. 1 Although the etiology of hypertensive disorders in pregnancy is not completely understood, abnormal placentation and endothelial dysfunction have been cited as the main pathophysiologic mechanisms associated with the disorder. 2 Heme oxygenase (HO) catalyzes the conversion of heme to bilirubin and carbon monoxide (CO). HO activity is found in most tissues, but is not evenly distributed. 3 The HO pathway may affect several physiological functions including vascular tone, oxidative stress and cellular proliferation. 3, 4 It has been suggested that HO plays a role in human placental throphoblast invasion 5 and vascular function control. 6 CO shares some of the physiochemical properties of nitric oxide (NO). 7 Like NO, CO has the ability to increase intracellular cyclic guanosine monophosphate (cGMP) production. Endogenous CO production under physiological conditions serves to regulate smooth muscle tone, 8 and may play a role in neurotransmission. 9 Exogenously added CO has been shown to increase the smooth muscle intracellular levels of cGMP and to cause endotheliumdependent vascular relaxation. 10 HO activity and CO levels were found to have an inverse effect on blood pressure in animal models. 11 Endogenous CO production can be estimated by measuring end tidal CO levels corrected for ambient CO (ETCOc). In humans, ETCOc levels were shown to be significantly lower in women with pregnancy-induced hypertension (PIH) and pre-eclampsia (PE) when compared to healthy third-trimester pregnant nonsmoking women. 12 However, this study did not control for significant differences in gestational age among the study and control groups, as well as for other possible confounding variables.
The purpose of this study was to evaluate the association of GH and PE with ETCOc levels and to determine the possible confounding effects of gestational age and maternal characteristics.
MATERIALS AND METHODS
ETCOc measurements were prospectively performed in two medical centers (Lucile Salter Packard Children's Hospital at Stanford University and MacDonald Women's Hospital at Cleveland). From May 1999 through March 2000, patients who attended the obstetric clinic in both centers were asked to participate in the study. Female staff members volunteered to serve as the nonpregnant controls. The Institutional Review Boards at each institution approved the study protocol and all participants gave their written informed consent.
The study group included 31 women with GH or PE classified according to the American College of Obstetrics and Gynecology criteria. 1 The women were recruited from a high-risk outpatient clinic. None were in active labor and none received magnesium or any other acute antihypertensive medications. Control groups included 46 nonpregnant women, 44 first-trimester and 48 thirdtrimester pregnant women. The women who served as controls were recruited from among healthy women, without uterine counteractions, who attended our outpatient low-risk antenatal clinic. The study and control groups included only nonsmoking healthy women between the ages of 18 and 35 years.
Exclusion criteria included chronic cardiovascular or renal disease, acute or chronic respiratory disease, chronic hypertension, fever or evidence of an infectious disease, pregestational diabetes, known hemolytic disease (other than HELLP syndrome) or multiple pregnancies.
ETCOc measurements were obtained using a portable automated CO analyzer (Natus s CO-Stat s End Tidal Breath Analyzer, Natus Medical Inc., San Carlos, CA). 13 Following instruction by one of the investigators and at least a 15-minute rest, each participant gave a 90-second breath exhale sample, collected and simultaneously analyzed, via a 5F catheter placed 0.5 cm into the anterior nares.
Demographic parameters that were collected included age, gravidity, parity, height, current body weight, pregestational weight and gestational age (for the pregnant patients). Physical parameters included presence of leg edema, systolic and diastolic blood pressure, and proteinuria measured by dipstick and 24-hour urine collection. HELLP syndrome was classified after the Mississippi group classification.
14 Statistical analysis was performed applying single factor analysis of variance (ANOVA) for continuous variables using Bonferroni multiple comparisons t-test for multiple groups or unpaired t-test for two groups or the Fisher exact tests for dichotomous data (Statview 4.02, Abacus Concepts Inc., Berkeley, CA). Statistical significance was assumed at p<0.05.
RESULTS
Maternal age was significantly higher in the GH/PE group and gravidity was significantly lower in the nonpregnant group when compared with the other groups (Table 1) . However, no correlation between maternal age or gravidity and ETCOc values were found when analyzed for all patients and for each group (r ¼ 0.009, p ¼ 0.19 and r ¼ 0.07, p ¼ 0.37, respectively). As expected, maternal body man index (BMI) was higher in the GH/PE group when compared with the nonpregnant and the first-trimester Hispanic patients. The mean gestational age of the GH/PE group did not differ from the mean gestational age of the third-trimester healthy women (33.2±3.6 weeks vs 33.6±3.8 weeks) ( Table 1) . Leg edema was more prevalent in women with GH/PE (86%) compared to only 20% in the healthy third-trimester group and none in the other two groups. Both mean systolic and diastolic blood pressure were significantly higher in the GH/PE group (Table 2) .
Mean±SD ETCOc measurements were significantly lower in the GH/PE group compared with first trimester (p ¼ 0.004), thirdtrimester normotensive pregnant women (p ¼ 0.001) and nonpregnant women (p ¼ 0.002) (1.36±0.30 vs 1.76±0.47, 1.72±0.42 and 1.78±0.54 ppm, respectively) ( Table 2 ). The ETCOc values were r1.6 ppm in 89% of GH/PE women compared with only 45, 54 and 46% of nonpregnant, first-and third-trimester normotensive pregnant women, respectively (p<0.05). The ETCOc measurements were not influenced by ethnicity, maternal age, parity, BMI, gestational age or presence of household smokers. In the two centers, the control groups had a similar mean ETCOc and the differences found remained significant when results for each center were analyzed separately ( Table 2 ). There was only one patient in the GH/PE group who had class 2 HELLP syndrome defined by low platelets and elevated liver enzymes (peripheral smear was not done). The ETCOc level of this patient was not statistically different from the average ETCOc level of the GH/PE group.
DISCUSSION
In this prospective study, we have shown that PE is associated with reduction in CO production as measured by lower ETCOc levels.
These findings are consistent with our previous observation showing significantly lower ETCOc levels in third-trimester preeclamptic patients. 12 However, in the previous study it was not possible to rule out the confounding effect of gestational age, maternal BMI, exposure to passive smoking or ethnic origin. Therefore, in contrast to the previous data, where the study and control groups differed significantly in their mean gestational age, 12 our current study shows that gestational age has no significant effect on ETCOc levels. Furthermore, exposure to passive smoking and differences in maternal BMI could not explain the observed association. In addition, while our earlier observation was made in a primarily Jewish Caucasian population, the present study confirmed these findings in two different populations in Cleveland (mainly African-American patients) and in Stanford (mainly Caucasian and Hispanic patients).
Lower activity of HO and lower levels of its byproduct CO may change the regulation of blood pressure and placental blood flow in PE. In the rat model, blood pressure elevation, which can be induced by injection of angiotensin II, is associated with HO induction in the renal tubules as a compensating mechanism. 15 Moreover, HO induction by hemine or L-arginine produces a reduction in blood pressure in the spontaneous hypertensive rat (SHR). 11 As with HO, inhibition of CO production by HO inhibitor zinc protoporphyrin IX (ZnPP-IX) causes an increase in blood pressure in SHR. 16 On the other hand, increased CO production is associated with a reduction in blood pressure 17 and with suppression of acute hypertensive response in SHR.
11
HO activity is not evenly distributed in different organs. 3 While PE is associated with reduced ETCOc levels, it is also linked with elevated HO protein expression and mRNA levels in the human uterus. 18 Increased HO activity may protect the uterus from the hypoxic injury 19 associated with PE. 20 On the other hand, decreased ETCOc levels in PE may be related to reduction in HO production in other organs such as the kidneys via reduced induction of HO secondary to lower angiotensin II levels. ETCOc measurements are accurate, 20 but may be influenced by various conditions. Tobacco smoke exposure may increase ETCOc measurements, from a mean±SD of 1.33±0.84 ppm in nonsmoking mothers to 1.95±0.98 in those exposed to passive smoking and 8.42±5.65 in women who smoke. 22 Our data are in agreement with previous data and show that passive exposure to tobacco smoke does not change ETCOc levels. 20 ETCOc levels are increased in hemolytic disorders 23 and, as a result, are expected to be elevated in women with HELLP syndrome. In our study population, only one patient had HELLP syndrome with an ETCOc level of 0.9 ppm, which is not statistically different from the PE group. However, this patient had both low platelets and elevated liver enzymes, but the presence of hemolysis was not proven by peripheral blood smear. It may be interesting to further evaluate the ETCOc levels during the development of HELLP, since ETCOc measurements may offer a sensitive clinical tool for assessing hemolysis.
21
Despite intensive research, there is currently no effective method to identify women at risk for PE. Genetic factors, 24 immunological factors such as tumor necrosis factor-a, 25 the placental peptides activin A and inhibin A, 26 and physical changes in Doppler ultrasound blood flow velocity 27 were all linked with PE. Yet, none of these factors is superior to clinical history or epidemiological variables for identifying individuals who are at increased risk for developing PE. Further longitudinal studies should be performed to determine whether the decline in ETCOc measurements heralds the clinical manifestation of PE. On the low background ETCOc levels prevalent among PE patients, ETCOc measurements may also be of value in determining whether mild hemolysis exists and thus aid in the early diagnosis of HELLP.
In summary, our data reveal that ETCOc levels do not change throughout pregnancy. However, as previously suggested, the ETCOc levels were found to be significantly lower in pregnancies complicated by PE. This association could not be explained by the confounding effect of gestational age, maternal BMI, exposure to passive smoking or ethnic origin.
